Conexeu Sciences Advanced Wound Device Manufacturing
The Reno-based firm has scaled up production for its Ten Minute Tissue device ahead of a planned 2027 FDA filing.
Updated on Oct. 6, 2026 in Biotech
Live Poll
Do you trust that medical device companies prioritize patient safety over their own commercial development goals?
Conexeu Sciences has successfully transitioned its Reno-based wound care device from process development to a controlled manufacturing phase. The preclinical-stage company recently confirmed that multiple test batches met key performance benchmarks for its Ten Minute Tissue product.
Why it matters
Scaling production is a critical milestone for the firm as it moves toward a regulatory 510(k) submission. Successful commercialization of this wound care technology depends on the company's ability to maintain these manufacturing standards for future market demand.
Conexeu Sciences successfully validated production batches for its investigational Ten Minute Tissue device. The firm is now preparing for a regulatory 510(k) review, which typically targets a 90-day performance goal following submission.
The players
Conexeu Sciences
A Reno-based, preclinical-stage medical device company developing the Ten Minute Tissue wound care product.
The details
Conexeu Sciences completed process development for the Ten Minute Tissue device, which is designed to transition into a gel within 10 minutes. The company is now producing representative samples to support biocompatibility and characterization testing required for regulatory approval. These efforts follow feedback received through the FDA's Q-Submission process, moving the startup closer to its anticipated 2027 regulatory milestones.
Timeline
October 6, 2026: Conexeu Sciences released a program update on manufacturing progress.
First Quarter 2027: The company plans to submit its 510(k) application to the FDA.
The Truckee Meadows View
Conexeu Sciences is following the established FDA 510(k) regulatory submission process to validate its medical device technology. This manufacturing shift represents a specific progression along the same pathway used by other emerging biotech firms seeking federal clearance for commercial hardware.
As Conexeu Sciences ramps up operations in the valley, the company is building the infrastructure necessary to eventually scale for market entry. Residents should watch for the upcoming Q1 2027 regulatory filing as a marker for the project's long-term viability in the local tech sector.
The takeaway
The company is moving from internal development to regulatory-grade manufacturing for its wound care technology. Keep an eye on the planned 510(k) submission in early 2027 as the primary indicator for the commercial success of the Ten Minute Tissue device.
Further reading
For more on the local life sciences sector, see our coverage in Biotech.
Live Poll
Do you trust that medical device companies prioritize patient safety over their own commercial development goals?
